Published in Brain on June 05, 2009
The link between the GBA gene and parkinsonism. Lancet Neurol (2012) 1.80
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol (2014) 1.37
The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep (2010) 1.28
Genetics of Parkinson disease and essential tremor. Curr Opin Neurol (2010) 0.96
Gaucher disease: insights from a rare Mendelian disorder. Discov Med (2012) 0.95
Greater risk of parkinsonism associated with non-N370S GBA1 mutations. J Inherit Metab Dis (2012) 0.91
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Genetically engineered mouse models of Parkinson's disease. Brain Res Bull (2011) 0.86
Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. Neurogenetics (2011) 0.81
The significance of GBA for Parkinson's disease. J Inherit Metab Dis (2014) 0.80
Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease. J Neurol (2012) 0.80
Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. FEBS Lett (2015) 0.78
Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration. PLoS Genet (2016) 0.77
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Rep (2014) 0.76
Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson's disease. J Hum Genet (2014) 0.76
Effect of GBA Mutations on Phenotype of Parkinson's Disease: A Study on Chinese Population and a Meta-Analysis. Parkinsons Dis (2015) 0.75
Glucocerebrosidase and parkinsonism: lessons to learn. J Neurol (2016) 0.75
The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Diseases (2017) 0.75
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A (1997) 4.89
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology (2008) 3.83
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol (2003) 2.17
Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci (1999) 2.12
Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem (1999) 1.92
Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res (2003) 1.88
Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A (1999) 1.81
Gait instability and fractal dynamics of older adults with a "cautious" gait: why do certain older adults walk fearfully? Gait Posture (2005) 1.77
Bilateral coordination of gait and Parkinson's disease: the effects of dual tasking. J Neurol Neurosurg Psychiatry (2009) 1.70
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology (2007) 1.70
Globus pallidus internus pallidotomy for generalized dystonia. Mov Disord (1997) 1.69
Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J Neurol (2005) 1.63
Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J Neurochem (2007) 1.60
Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. Gastroenterology (1999) 1.43
Quantitative anal sphincter EMG in multisystem atrophy and 100 controls. J Neurol Neurosurg Psychiatry (2001) 1.42
Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry (2000) 1.42
An instrumented timed up and go: the added value of an accelerometer for identifying fall risk in idiopathic fallers. Physiol Meas (2011) 1.26
Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia. J Clin Neurosci (2003) 1.20
Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord (2001) 1.13
Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol (2004) 1.09
Treadmill training for the treatment of gait disturbances in people with Parkinson's disease: a mini-review. J Neural Transm (Vienna) (2008) 1.09
Subjective memory complaints in elders: depression, anxiety, or cognitive decline? Acta Neurol Scand (2012) 1.08
Altered baroreflex responses in alpha7 deficient mice. Behav Brain Res (2000) 1.07
The prevalence and expression of inherited connexin 26 mutations associated with nonsyndromic hearing loss in the Israeli population. Hum Genet (2000) 1.05
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics (2009) 1.05
Hand rhythmic tapping and timing in Parkinson's disease. Parkinsonism Relat Disord (2004) 1.02
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol (2001) 0.96
[Botulinum toxin as a powerful new tool in the treatment of focal dystonia]. Harefuah (1991) 0.96
The challenge of evaluating freezing of gait in patients with Parkinson's disease. Br J Neurosurg (2008) 0.94
Tetrabenazine treatment in movement disorders. Clin Neuropharmacol (2004) 0.94
High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Genet Test (1998) 0.94
A wearable system to assist walking of Parkinson s disease patients. Methods Inf Med (2009) 0.94
Catecholamine outflow from mouse and rat brain slice preparations evoked by nicotinic acetylcholine receptor activation and electrical field stimulation. Br J Pharmacol (2007) 0.93
The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. Genet Test (2000) 0.92
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm (Vienna) (2004) 0.92
The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology (2001) 0.91
Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm (Vienna) (2001) 0.90
Targeting the subthalamic nucleus. Stereotact Funct Neurosurg (2001) 0.89
The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet (1998) 0.88
Murine prosaposin: expression in the reproductive system of a gene implicated in human genetic diseases. Cell Mol Biol (Noisy-le-grand) (1993) 0.88
Vasomotor reactivity as a predictor for syncope in patients with orthostatism. Acta Neurol Scand (2011) 0.86
Olanzapine in Huntington's disease. Acta Neurol Scand (2002) 0.86
Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord (2002) 0.86
Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol (2007) 0.85
Nicotinic acetylcholine receptor-subunit mRNAs in the mouse superior cervical ganglion are regulated by development but not by deletion of distinct subunit genes. J Neurosci Res (2008) 0.85
Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease. J Neural Transm (Vienna) (2003) 0.85
Bone scintigraphy in two siblings with pulmonary alveolar microlithiasis. Br J Radiol (1985) 0.83
Cellular prion protein co-localizes with nAChR beta4 subunit in brain and gastrointestinal tract. Eur J Neurosci (2008) 0.83
Progressive nature of a higher level gait disorder: a 3-year prospective study. J Neurol (2010) 0.83
Visuomotor control abnormalities in patients with unilateral parkinsonism. Neurology (1998) 0.83
Analysis of the Hoxd-3 gene: structure and localization of its sense and natural antisense transcripts. DNA Cell Biol (1995) 0.83
Effect of fetal gender on first trimester markers and on Down syndrome screening. Prenat Diagn (2001) 0.82
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand (2003) 0.82
Gait and mental function: the interplay between walking, behavior and cognition. J Neural Transm (Vienna) (2007) 0.82
Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach. J Neurol (2012) 0.82
A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm (Vienna) (2013) 0.82
Cross-sectional study of the prevalence of Parkinson's disease in the Kibbutz movement in Israel. Neuroepidemiology (2001) 0.82
Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome. Mov Disord (1993) 0.81
The effects of reducing fear of falling on locomotion in older adults with a higher level gait disorder. J Neural Transm (Vienna) (2007) 0.81
Subjective memory decline in healthy community-dwelling elders. What does this complain mean? Acta Neurol Scand (2009) 0.81
Synchrony of rest tremor in multiple limbs in parkinson's disease: evidence for multiple oscillators. J Neural Transm (Vienna) (2001) 0.81
High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm (Vienna) (2011) 0.81
Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol (1997) 0.81
Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. Adv Neurol (1993) 0.80
Homeogenes in mammalian development and the evolution of the cranium and central nervous system. FASEB J (1990) 0.80
Pharyngoconjunctival fever. Arch Dis Child (1984) 0.80
Different phenotypic expression in monozygotic twins with Huntington disease. Am J Med Genet A (2004) 0.80
Familial adenomatous polyposis at the Tel Aviv Medical Center: demographic and clinical features. Fam Cancer (2001) 0.80
Absence of mutations in ATM, the gene responsible for ataxia telangiectasia in patients with cerebellar ataxia. J Neurol (1999) 0.80
Quality of life and gender identity in Parkinson's disease. J Neural Transm (Vienna) (2005) 0.80
Hemiparkinsonism-hemiatrophy syndrome may mimic early-stage cortical-basal ganglionic degeneration. Mov Disord (1992) 0.79
An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment. J Neural Transm (Vienna) (2000) 0.79
Young women with PD: a group work experience. Soc Work Health Care (2000) 0.78
Nicotinic acetylcholine receptors control acetylcholine and noradrenaline release in the rodent habenulo-interpeduncular complex. Br J Pharmacol (2014) 0.78
First trimester PAPP-A in the detection of non-Down syndrome aneuploidy. Prenat Diagn (2001) 0.78
[Botulinum toxin injection effective for post-peripheral facial nerve palsy synkinesis]. Harefuah (1998) 0.78
Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. Clin Exp Rheumatol (2010) 0.77
Computer resources for the clinical and molecular geneticist. Methods Mol Biol (2000) 0.77
Deprenyl monotherapy improves visuo-motor control in early parkinsonism. J Neural Transm Suppl (1998) 0.77
Is heart rate variability related to gait impairment in patients with Parkinson's disease? A pilot study. Parkinsonism Relat Disord (2009) 0.77
Introducing a new definition of a near fall: intra-rater and inter-rater reliability. Gait Posture (2013) 0.77
Normal apoptosis levels in mice expressing one alpha7 nicotinic receptor null and one L250T mutant allele. Neuroreport (2001) 0.77
R-R interval variation in Parkinson's disease and multiple system atrophy. Acta Neurol Scand (2004) 0.77
Hormones and Parkinson's disease. Neurology (1995) 0.76
Lesioning the subthalamic nucleus in the treatment of Parkinson's disease. Stereotact Funct Neurosurg (2001) 0.76
Constitutional mosaicism for a chromosome 9 inversion resulting in recombinant aneusomy in an offspring. Am J Med Genet (1997) 0.76
Myotonic dystrophy with unilateral bulbar involvement. J Neurol Neurosurg Psychiatry (1988) 0.75
The use of botulinum toxin to treat "striatal" toes. J Neurol Neurosurg Psychiatry (1994) 0.75
[Neurosurgical aspects in achondroplasia: evaluation and treatment]. Harefuah (2001) 0.75
Murine prosaposin: expression in the reproductive system of a gene implicated in human genetic disease. Cell Mol Biol (Noisy-le-grand) (1994) 0.75
Subdivision of essential tremor patients according to physiologic characteristics. Acta Neurol Scand (2004) 0.75
[Botulinum toxin for palatal myoclonus and spastic dysphonia]. Harefuah (1993) 0.75
[Plasmapheresis in neurological diseases]. Harefuah (1987) 0.75